Prostate Cancer
Sales of Abarelix for prostate cancer forecast to reach $450 million
Published in Drug Week, February 16th, 2007
Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 U.S. Food & Drug Administration approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-02-16)
More Articles from Drug Week
- Cancer Therapy
MGI PHARMA reports publication of phase III data for Saforis Powder in UpTec - Depression
Novartis/Servier drug expected to achieve blockbuster status in antidepressant market - Market Analysis
Cutting Edge Information reports 42% of pharma firms outsource phase IV research - Alzheimer Disease Therapy
Saitama Medical University, Department of Pharmacology details research in Alzheimer disease therapy - Angiotensins
Research from Monash University has provided new information about angiotensins - Angiotensins
Research from University of Ioannina, Division of Cardiology has provided new information about angiotensins - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
